To analyze the impact of the more potent P2Y12-inhibitors prasugrel and ticagrelor (compared to clopidogrel) and DES (compared to BMS) in CKD-patients on outcome, event rates (in-hospital and at 1-year) were first compared in a univariate model. This evidence concerns the gene P2RY12 and chronic kidney disease.